Cathay International Holdings Limited (LSE: CTI.L") was originally incorporated in Bermuda. The Company's common shares are premium listed on the London Stock Exchange.

The Group is an investment holding company and an operator and investor in the growing healthcare sector in the PRC. The Group employs more than 1,600 people across China, including over 20 specialist corporate and business development staff based at the Hong Kong and Shenzhen offices.


Business Strategy

Cathay is an investor and operator in the growing healthcare sector in the PRC. The Company and its subsidiaries (collectively the “Group”) aim to leverage on growth opportunities in the strong and growing domestic demand for high quality healthcare products in China and build its portfolio companies into market sector leaders with competitive edge.

Cathay's business portfolio includes:

Lansen, listed on the main board of the Hong Kong Exchange, is a leading pharmaceutical company in China which focuses on the rheumatic specialty prescription western pharmaceuticals for the treatment of autoimmune rheumatic diseases and dermatology indications. Lansen group is engaged in the manufacture, distribution and development of rheumatic drugs, with a leading position in the disease-modifying anti-rheumatic drugs ("DMARDs") market in the PRC. Lansen is also engaged in the production and sales of plant extracts and healthcare products.
Botai is engaged in collagen products and has received the first ever domestic production license in China for collagen injectable filler from SFDA in China. Modification and expansion of production facilities expected to complete in 2015.

Haizi is engaged in the manufacture, marketing and sales of inositol and its by-product, di-calcium phosphate and has capacity to produce 2,500 tonnes of inositol per annum, second largest in the PRC.
Natural Dailyhealth
Natural Dailyhealth is engaged in the production and sales of plant extracts, such as bilberry, gingko extract and ginseng extract, for use as key active ingredients in healthcare products.
The Crowne Plaza Hotel & Suites Landmark Shenzhen

This is a leading luxury business hotel, managed by InterContinental Hotels Group, and located in the Luohu district of Shenzhen in the PRC.